Brokerages Set Liquidia Corporation (NASDAQ:LQDA) PT at $38.56

by · The Markets Daily

Liquidia Corporation (NASDAQ:LQDA – Get Free Report) has earned a consensus recommendation of “Moderate Buy” from the ten ratings firms that are currently covering the stock, MarketBeat Ratings reports. Two analysts have rated the stock with a sell recommendation, seven have given a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $38.5556.

Several equities analysts have recently issued reports on LQDA shares. Needham & Company LLC boosted their price target on shares of Liquidia from $36.00 to $52.00 and gave the company a “buy” rating in a report on Tuesday, November 4th. Raymond James Financial reiterated a “strong-buy” rating and set a $47.00 target price on shares of Liquidia in a report on Tuesday, November 4th. HC Wainwright increased their price target on Liquidia from $35.00 to $50.00 and gave the stock a “buy” rating in a report on Tuesday, November 4th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Liquidia in a research report on Wednesday, October 8th. Finally, Jefferies Financial Group reiterated a “buy” rating and set a $45.00 price objective on shares of Liquidia in a report on Monday, November 3rd.

Read Our Latest Analysis on Liquidia

Insider Transactions at Liquidia

In related news, insider Rajeev Saggar sold 71,381 shares of the business’s stock in a transaction on Wednesday, November 5th. The shares were sold at an average price of $27.00, for a total value of $1,927,287.00. Following the sale, the insider directly owned 176,549 shares of the company’s stock, valued at approximately $4,766,823. The trade was a 28.79% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Jason Adair sold 35,656 shares of the company’s stock in a transaction on Tuesday, November 18th. The stock was sold at an average price of $30.03, for a total transaction of $1,070,749.68. Following the completion of the transaction, the insider directly owned 174,998 shares of the company’s stock, valued at approximately $5,255,189.94. The trade was a 16.93% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 169,644 shares of company stock valued at $4,500,450. 26.50% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the company. Tudor Investment Corp ET AL acquired a new stake in Liquidia in the 3rd quarter valued at approximately $1,536,000. FNY Investment Advisers LLC acquired a new stake in shares of Liquidia in the third quarter valued at approximately $34,000. Caxton Associates LLP acquired a new stake in shares of Liquidia in the third quarter valued at approximately $389,000. TCG Crossover Management LLC bought a new stake in shares of Liquidia in the third quarter worth $38,887,000. Finally, Voloridge Investment Management LLC acquired a new position in Liquidia during the third quarter worth $12,571,000. 64.54% of the stock is currently owned by institutional investors.

Liquidia Stock Performance

Shares of LQDA stock opened at $34.49 on Friday. The stock has a market cap of $3.00 billion, a PE ratio of -23.95 and a beta of 0.48. The stock has a 50-day moving average of $30.37 and a 200-day moving average of $24.23. The company has a debt-to-equity ratio of 6.19, a current ratio of 2.20 and a quick ratio of 1.96. Liquidia has a one year low of $11.26 and a one year high of $36.41.

Liquidia (NASDAQ:LQDA – Get Free Report) last issued its quarterly earnings data on Monday, November 3rd. The company reported ($0.04) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.41. The firm had revenue of $54.34 million during the quarter, compared to analysts’ expectations of $18.86 million. Liquidia had a negative net margin of 176.04% and a negative return on equity of 296.78%. The business’s quarterly revenue was up 1106.7% on a year-over-year basis. As a group, sell-side analysts expect that Liquidia will post -1.51 earnings per share for the current year.

About Liquidia

(Get Free Report)

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).

Read More